[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624174":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":26,"responsibleParty":37,"collaborators":26,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":43,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":26,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":67,"whyStopped":26,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":26},{"fullName":5,"class":6},"Hayat Abad Medical Complex, Peshawar","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tofacitinib 10 mg Twice Daily","EXPERIMENTAL","Participants will receive oral tofacitinib 10 mg twice daily for 12 weeks. Clinical response will be assessed using the SALT score at baseline and at week 12. Efficacy is defined as \\>50% improvement in SALT score from baseline.",[13],"Drug: Tofacitinib",{"label":15,"type":16,"description":17,"interventionNames":18},"Methotrexate 0.2-0.4 mg\u002Fkg Weekly","ACTIVE_COMPARATOR","Participants will receive oral methotrexate 0.2-0.4 mg\u002Fkg once weekly for 12 weeks with routine follow-up and laboratory monitoring for adverse effects as per institutional protocol. Clinical response will be assessed using the SALT score at baseline and at week 12. Efficacy is defined as \\>50% improvement in SALT score from baseline.",[19],"Drug: Methotrexate",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Tofacitinib","Oral tofacitinib 10 mg twice daily for 12 weeks.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Methotrexate","Oral methotrexate 0.2-0.4 mg\u002Fkg once weekly for 12 weeks, with routine monitoring for adverse effects as per institutional protocol.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Hira Rehman, FCPS","CONTACT","03359849292","khira420.hr@gmail.com",{"type":38,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Hira Rehman","PGR","100624174","phase-4-tofacitinib-vs-methotrexate-for-severe-alopecia-areata-tofa-mtx-aa-100624174",false,"NCT07406204","Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)","Comparative Clinical Efficacy of Tofacitinib Versus Methotrexate in Severe Alopecia Areata, Alopecia Totalis, and Alopecia Universalis: A Randomized Controlled Trial","TOFA-MTX-AA","Inclusion Criteria:\n\nAdults aged 18-60 years.\n\nClinical diagnosis of severe alopecia areata, alopecia totalis, or alopecia universalis (as per protocol\u002Foperational definition), confirmed by a consultant dermatologist.\n\nEither sex.\n\nAble and willing to provide written informed consent.\n\nExclusion Criteria:\n\nCurrently receiving or recently used any systemic treatment intended for hair regrowth for alopecia areata (e.g., systemic corticosteroids, immunosuppressants, JAK inhibitors).\n\nPregnant women.\n\nHistory or clinical evidence of renal, hepatic, or pulmonary disease.\n\nAny condition that, in the investigator's judgment, makes participation unsafe or interferes with adherence to the study protocol.","ALL","18 Years","60 Years",{"count":53,"type":54},78,"ESTIMATED","INTERVENTIONAL",[57],"PHASE4","This study will compare two oral medicines-tofacitinib and methotrexate-for treating severe alopecia areata, including alopecia totalis (loss of all scalp hair) and alopecia universalis (loss of scalp and body hair). Alopecia areata is an autoimmune condition that can cause significant hair loss and emotional distress.\n\nAdults aged 18 to 60 years with severe disease will be enrolled at the Department of Dermatology, MTI-Hayatabad Medical Complex, Peshawar, after ethical approval and written informed consent. Participants will be randomly assigned to receive either tofacitinib 10 mg twice daily or methotrexate 0.2-0.4 mg\u002Fkg once weekly for 12 weeks.\n\nThe main outcome will be improvement in hair loss measured by the Severity of Alopecia Tool (SALT) score. Treatment will be considered effective if there is more than 50% improvement in SALT score from baseline at the end of 12 weeks. Safety will be monitored during follow-up visits. The findings may help guide treatment decisions for severe alopecia areata in our local population.",[60,61,62],"Alopecia Areata","Alopecia Totalis (AT)","Alopecia Universalis",[23,28,64,65,66],"Janus Kinase Inhibitor","Severe Alopecia Areata","Autoimmune Hair Loss","NOT_YET_RECRUITING","2026-02-05",{"date":70,"type":71},"2026-02-12","ACTUAL",{"date":73,"type":54},"2026-02-15",{"date":75,"type":54},"2026-08-15",{"name":5,"class":6}]